StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Lynparza (olaparib by Year

Lynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. sales ($M) ($M)

Merck Lynparza (olaparib: $683M in FY2025, up 9.1% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
683
Period ended Dec 31, 2025
Change on a year earlier
+9.1%
626 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Alliance Revenue – Lynparza (2) | 1,450 | 1,311 | 11 | 683 | 626 | 9 | 767 | 685 | 12”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLynparza (olaparib — AstraZeneca oncology alliance revenue) — U.S. sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025683+9.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024626+3.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023607+3.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022584+13.4%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 2021515+23.5%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 2020417+55.0%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 2019269+111.8%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018127–Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 20170–Form 10-K (filed 2020-02-26) ↗
FY2016Dec 31, 20160–Form 10-K (filed 2019-02-27) ↗

Breakdown

What makes up lynparza (olaparib

Cite this data

StockData. (2026). Merck Lynparza (olaparib ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lynparza-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.